AASLD/EASL Special Conference on Hepatitis C, Sheraton New York Times Square Hotel September 12

AASLD/EASL Special Conference on Hepatitis C, Sheraton New York Times Square Hotel September 12 - 13, 2014

PR Newswire

NEW YORK, Sept. 11, 2014

NEW YORK, Sept. 11, 2014 /PRNewswire/ -- The AASLD/EASL Special Conference on Hepatitis C will discuss new therapeutic options that can cure the vast majority of patients with HCV, insights on global epidemiology, barriers to care, and potential solutions to improve global access to therapy.

Members of the media interested in attending the conference may apply for a press pass by submitting their registration request and credential information to Ann Haran at aharan@aasld.org.

Join us in New York City as we discuss two major developments—the recommendation for birth cohort screening and the recent approval of all-oral treatment regimens—that are poised to change the landscape of HCV patient care. This special conference brings together a distinguished faculty from around the world to discuss the pathogenesis, diagnosis, and treatment of the disease.

New York, NY: September 12 - 13, 2014

September 12 8:00 am – 5:30 pm

September 13 8:00 am – 12:15 pm

Open Forum and Q&A on Access to Care for Patients with HCV: Friday, September 12, 2014, 5:45 pm

Attendees: Registered attendees and registered media. Only registered attendees of the conference may attend the open forum and Q&A session.

Speakers will address all questions concerning treatment of HCV in addition to access to care.
Telephone attendees: Persons wishing to participate in the public forum by telephone may to respond to this event announcement by contacting aharan@aasld.org and requesting registration to the public forum only.

It is estimated that between 3 and 4 million Americans are infected with HCV and have chronic liver disease as a result. Recently approved direct-acting antivirals are extremely effective in treating the virus and hold great potential for cure. However, limitations of workforce and societal resources may limit the feasibility of treating all patients within a short period of time. AASLD is aware of the short-term financial burden placed on payers by the cost of these drugs. To fully address the issue of cost, healthcare practitioners and systems, insurers, government, and especially the pharmaceutical companies all need to share the responsibility of ridding our population of this infection.

Click here for AASLD's complete position statement on the recently released HCV Guidance.

About AASLDFounded in 1950, AASLD is a medical subspecialty society representing clinicians and researchers in liver disease. The work of our members has laid the foundation for the development of drugs used to treat patients with viral hepatitis. Access to care and support of liver disease research are at the center of AASLD's advocacy efforts. AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease.

Contact: Ann Haran, 703-299-9766, aharan@aasld.org

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.

SOURCE American Association for the Study of Liver Diseases (AASLD)